| P50 | author | Hye-Eun Kim | Q42920357 |
| | Sung-Gyoo Park | Q83144987 |
| P2093 | author name string | Cho-Rong Lee | |
| | Jung-Ah Kang | |
| | Taewoo Yang | |
| | Yegyun Choi | |
| P2860 | cites work | Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs | Q24294766 |
| | The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects | Q24306539 |
| | TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis | Q24533281 |
| | Potentiation of the T-lymphocyte response to mitogens. I. The responding cell | Q24679275 |
| | Two different point mutations in ABL gene ATP-binding domain conferring primary imatinib resistance in a chronic myeloid leukemia (CML) patient: A case report | Q24800045 |
| | Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer | Q28196352 |
| | The balance between IL-1 and IL-1Ra in disease | Q28200818 |
| | Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics | Q28205012 |
| | Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia | Q28236440 |
| | Properties and usefulness of the original K-562 human myelogenous leukemia cell line | Q28264733 |
| | IL-1 is required for tumor invasiveness and angiogenesis | Q28594748 |
| | PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice | Q33608760 |
| | The biology of chronic myeloid leukemia | Q33686190 |
| | The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. | Q33737469 |
| | Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein | Q34136730 |
| | A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. | Q34170309 |
| | Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. | Q34231598 |
| | Many actions of cyclooxygenase-2 in cellular dynamics and in cancer | Q34539982 |
| | Loss of p53 impedes the antileukemic response to BCR-ABL inhibition | Q34585293 |
| | Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia | Q34622576 |
| | Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib | Q35071103 |
| | Regulation of the c-Abl and Bcr-Abl tyrosine kinases | Q35621355 |
| | Rottlerin enhances IL-1β-induced COX-2 expression through sustained p38 MAPK activation in MDA-MB-231 human breast cancer cells | Q35667259 |
| | Prognostic impact of cyclooxygenase-2 in breast cancer. | Q35691963 |
| | Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia | Q35903505 |
| | Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl | Q36365946 |
| | Cytokines as a key component of cancer-related inflammation | Q37243051 |
| | Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations | Q37623532 |
| | BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance | Q40306743 |
| | The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein | Q40351786 |
| | Regulation of hematopoietic growth factor production by genetically modified human bone marrow stromal cells expressing interleukin-1beta antisense RNA. | Q40768282 |
| | Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation | Q40837798 |
| | Mutator phenotype of BCR--ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta | Q40951632 |
| | Regulation of hematopoiesis by microvascular endothelium | Q41708973 |
| | Imatinib resistance in multidrug-resistant K562 human leukemic cells | Q43407353 |
| | Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha | Q44361989 |
| | Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia | Q44611047 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | imatinib | Q177094 |
| | chronic myeloid leukemia | Q729735 |
| P304 | page(s) | 358-368 | |
| P577 | publication date | 2016-01-25 | |
| P1433 | published in | FEBS Letters | Q1388051 |
| P1476 | title | Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance | |
| P478 | volume | 590 | |